Blarcamesine hydrochloride (AVex-73 hydrochloride) is a Sigma-1 Receptor agonist (IC50: 860 nM).

The pretreatment of Anavex 2-73 (1/3 mg/kg) dose-dependently reduces the scopolamine-induced alternation deficit. The pretreatment with Anavex 2-73 (>0.3 mg/kg) dose-dependently and significantly attenuates the impairments of step-through latency[1]. The Anavex 2-73 (1?mg/kg) dose-dependently blocks the recognition memory deficit. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Anavex 2-73 (0.1/1?mg/kg). Seven days after injections, Anavex 2-73 attenuates the decrease in Ser9 phosphorylation induced by the peptide (0.3/1?mg/kg)[2].

Drugs (including Anavex 2-73) are solubilized in physiological saline at the concentration of 5?mg/mL.Male mice aged 7-9 weeks and weighing 32±2?g are used. Drugs (including Anavex 2-73) are brought up to each dose by dilution and injected in a volume of 100?μL/20?g body weight. Animals are used between days 1 and 9 after i.c.v. injections for behavioral testing or killed before biochemical measures.